Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development
Affectis Pharmaceuticals AG
Asahi Kasei Pharma Corp
Axxam SpA
Biosceptre Intertiol Ltd
Evotec SE
Integral Molecular Inc
Johnson & Johnson
Lead Discovery Center GmbH
MindImmune Therapeutics Inc
MyoTherix Inc
Suven Life Sciences Ltd
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles
AFC-5128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKP-23494954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-03s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-06v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-07v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVT-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5446 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-55308942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Antagonize P2X7 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small molecule to Antagonize P2X7 for Multiple Sclerosis and Epilepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X7 for Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X7 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2018: Update on phase I trial of vaccine BIL06v
Aug 21, 2018: Initiation of Biosceptre’s phase 1 clinical trial for first-in-class oncology vaccine BIL06v
Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists
Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401
Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Affectis Pharmaceuticals AG, H2 2019
Pipeline by Asahi Kasei Pharma Corp, H2 2019
Pipeline by Axxam SpA, H2 2019
Pipeline by Biosceptre International Ltd, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Lead Discovery Center GmbH, H2 2019
Pipeline by MindImmune Therapeutics Inc, H2 2019
Pipeline by MyoTherix Inc, H2 2019
Pipeline by Suven Life Sciences Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019